Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramantamig plus Daratumumab in Newly Diagnosed Multiple Myeloma
NCT07665450Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of ramantamig in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-Free Survival at 62 months and Percentage of Participants Achieving 12-Month Minimal Residual Disease-Negative Complete Response. Started Sep 2026; status: recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07665450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665450.